Clinical significance of decreased programmed cell death 4 expression in patients with giant cell tumors of the bone

Gao,Fei; Zhang,Wei; Ding,Lingling; Zhao,Miaoqing; Ma,Zhe; Huang,Shanying

doi:10.3892/ol.2018.9087

Clinical significance of decreased programmed cell death 4 expression in patients with giant cell tumors of the bone

Authors:
- Fei Gao
- Wei Zhang
- Lingling Ding
- Miaoqing Zhao
- Zhe Ma
- Shanying Huang
View Affiliations

Affiliations: The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Shandong University Qilu Hospital, Jinan, Shandong 250012, P.R. China, Department of Orthopedics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Center for Reproductive Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Ultrasound, Shandong University Qilu Hospital, Jinan, Shandong 250012, P.R. China
Published online on: July 5, 2018 https://doi.org/10.3892/ol.2018.9087
Pages: 3805-3811
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Programmed cell death 4 (PDCD4) has been recognized as a novel tumor suppressor gene, which inhibits the activation and translation of activator protein (AP)‑1. Dysregulated expression of PDCD4 is also involved in various human tumors and is linked to tumor progression and development. However, the function and clinical implication of PDCD4 in giant cell tumors of the bone (GCTBs) has not been previously investigated. In the present study, PDCD4 expression was determined in 83 samples of GCTBs at mRNA and protein levels by quantitative reverse transcription‑polymerase chain reaction, western blotting and immunohistochemistry. The results demonstrated that PDCD4 mRNA expression was reduced in 63% of GCTB samples (17/27) and protein expression was decreased in 65% of samples (54/83), compared with adjacent non‑tumor tissues. Furthermore, decreased expression of PDCD4 was significantly associated with certain clinicopathological characteristics, including the Campanacci grade and recurrence. A strong negative correlation was determined between PDCD4 expression and the Ki‑67 positive rate in GCTBs (r=‑0.6392; P<0.001). The results of the present study suggest that PDCD4 may serve a role in the malignant progression of human GCTBs and may be an important prediction factor for prognosis.

View Figures

View References

1	Turcotte RE: Giant cell tumor of bone. Orthop Clin North Am. 37:35–51. 2006. View Article : Google Scholar : PubMed/NCBI
2	Xu M, Song ZG, Xu CX, Rong GH, Fan KX, Chen JY, Zhang W, Jia JP, Han G, Wang W, et al: IL-17A stimulates the progression of giant cell tumors of bone. Clin Cancer Res. 19:4697–4705. 2013. View Article : Google Scholar : PubMed/NCBI
3	Müller DA, Beltrami G, Scoccianti G, Campanacci DA, Franchi A and Capanna R: Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series. World J Surg Oncol. 14:2812016. View Article : Google Scholar : PubMed/NCBI
4	Karpik M: Giant cell tumor (tumor gigantocellularis, osteoclastoma)-epidemiology, diagnosis, treatment. Ortop Traumatol Rehabil. 12:207–215. 2010.(In English, Polish). PubMed/NCBI
5	Muramatsu K, Ihara K and Taguchi T: Treatment of giant cell tumor of long bones: Clinical outcome and reconstructive strategy for lower and upper limbs. Orthopedics. 32:4912009. View Article : Google Scholar : PubMed/NCBI
6	Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, Hardes J and Gosheger G: Giant cell tumor of bone: Treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 134:969–978. 2008. View Article : Google Scholar : PubMed/NCBI
7	Dominkus M, Ruggieri P, Bertoni F, Briccoli A, Picci P, Rocca M and Mercuri M: Histologically verified lung metastases in benign giant cell tumours-14 eases from a single institution. Int Orthop. 30:499–504. 2006. View Article : Google Scholar : PubMed/NCBI
8	Van der Heijden L, Dijkstra PDS, Blay JY and Gelderblom H: Giant cell tumour of bone in the denosumab era. Eur J Cancer. 77:75–83. 2017. View Article : Google Scholar : PubMed/NCBI
9	Yamamoto H, Iwasaki T, Yamada Y, Matsumoto Y, Otsuka H, Yoshimoto M, Kohashi K, Taguchi K, Yokoyama R, Nakashima Y and Oda Y: Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. Hum Pathol. 73:41–50. 2018. View Article : Google Scholar : PubMed/NCBI
10	Lankat-Buttgereit B and Göke R: The tumour suppressor Pdcd4: Recent advances in the elucidation of function and regulation. Biol Cell. 101:309–317. 2009. View Article : Google Scholar : PubMed/NCBI
11	Yasuda M, Nishizawa T, Ohigashi H, Tanaka T, Hou DX, Colburn NH and Murakami A: Linoleic acid metabolite suppresses skin inflammation and tumor promotion in mice: Possible roles of programmed cell death 4 induction. Carcinogenesis. 30:1209–1216. 2009. View Article : Google Scholar : PubMed/NCBI
12	Hsu TC, Young MR, Cmarik J and Colburn NH: Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med. 28:1338–1348. 2000. View Article : Google Scholar : PubMed/NCBI
13	Loh PG, Yang HS, Walsh MA, Wang Q, Wang X, Cheng Z, Liu D and Song H: Structural basis for translational inhibition by the tumour suppressor Pdcd4. EMBO J. 28:274–285. 2009. View Article : Google Scholar : PubMed/NCBI
14	Hilliard A, Hilliard B, Zheng SJ, Sun H, Miwa T, Song W, Göke R and Chen YH: Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4. J Immunol. 177:8095–8102. 2006. View Article : Google Scholar : PubMed/NCBI
15	Jansen AP, Camalier CE and Colburn NH: Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res. 65:6034–6041. 2005. View Article : Google Scholar : PubMed/NCBI
16	Zhang Z, Wang J, Li J, Wang X and Song W: MicroRNA-150 promotes cell proliferation, migration, and invasion of cervical cancer through targeting PDCD4. Biomed Pharmacother. 97:511–517. 2018. View Article : Google Scholar : PubMed/NCBI
17	Hu X, Wang Y, Liang H, Fan Q, Zhu R, Cui J, Zhang W, Zen K, Zhang CY, Hou D, et al: miR-23a/b promote tumor growth and suppress apoptosis by targeting PDCD4 in gastric cancer. Cell Death Dis. 8:e30592017. View Article : Google Scholar : PubMed/NCBI
18	Gao F, Zhang P, Zhou C, Li J, Wang Q, Zhu F, Ma C, Sun W and Zhang L: Frequent loss of PDCD4 expression in human glioma: Possible role in the tumorigenesis of glioma. Oncol Rep. 17:123–128. 2007.PubMed/NCBI
19	Huang H, Wang X, Wang C, Zhuo L, Luo S and Han S: The miR-93 promotes proliferation by directly targeting PDCD4 in hepatocellular carcinoma. Neoplasma. 64:770–777. 2017. View Article : Google Scholar : PubMed/NCBI
20	Ding L, Zhang X, Zhao M, Qu Z, Huang S, Dong M and Gao F: An essential role of PDCD4 in progression and malignant proliferation of gastrointestinal stromal tumors. Med Oncol. 29:1758–1764. 2012. View Article : Google Scholar : PubMed/NCBI
21	Wang Y, Ding L, Zhang X, Zhao M, Qu Z, Huang S, Zhang Y, Li Y and Gao F: Clinical significance of programmed cell death 4 expression in malignant progression of human nasal inverted papillomas. Med Oncol. 29:2505–2011. 2012. View Article : Google Scholar : PubMed/NCBI
22	Campanacci M, Baldini N, Boriani S and Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am. 69:106–114. 1987. View Article : Google Scholar : PubMed/NCBI
23	Chadderton T, Wilson C, Bewick M and Glück S: Evaluation of three rapid RNA extraction reagents: Relevance for use in RT-PCR's and measurement of low level gene expression in clinical samples. Cell Mol Biol (Noisy-le-grand). 43:1227–1234. 1997.PubMed/NCBI
24	Culley DE, Kovacik WP Jr, Brockman FJ and Zhang W: Optimization of RNA isolation from the archaebacterium Methanosarcina barkeri and validation for oligonucleotide microarray analysis. J Microbiol Methods. 67:36–43. 2006. View Article : Google Scholar : PubMed/NCBI
25	Antal I, Sápi Z and Szendröi M: The prognostic significance of DNA cytophotometry and proliferation index (Ki-67) in giant cell tumors of bone. Int Orthop. 23:315–319. 1999. View Article : Google Scholar : PubMed/NCBI
26	Raskin KA, Schwab JH, Mankin HJ, Springfield DS and Hornicek FJ: Giant cell tumor of bone. J Am Acad Orthop Surg. 21:118–126. 2013. View Article : Google Scholar : PubMed/NCBI
27	Gamberi G, Serra M, Ragazzini P, Magagnoli G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci P and Benassi MS: Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep. 10:351–356. 2003.PubMed/NCBI
28	Pennelli G, Galuppini F, Barollo S, Cavedon E, Bertazza L, Fassan M, Guzzardo V, Pelizzo MR, Rugge M and Mian C: The PDCD4/miR-21 pathway in medullary thyroid carcinoma. Hum Pathol. 46:50–57. 2015. View Article : Google Scholar : PubMed/NCBI
29	Fassan M, Pizzi M, Battaglia G, Giacomelli L, Parente P, Bocus P, Ancona E and Rugge M: Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis. J Clin Pathol. 63:692–696. 2010. View Article : Google Scholar : PubMed/NCBI
30	Wang WQ, Zhang H, Wang HB, Sun YG, Peng ZH, Zhou G, Yang SM, Wang RQ and Fang DC: Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling pathway. Mol Diagn Ther. 14:155–161. 2010. View Article : Google Scholar : PubMed/NCBI
31	Gao F, Wang X, Zhu F, Wang Q, Zhang X, Guo C, Zhou C, Ma C, Sun W, Zhang Y, et al: PDCD4 gene silencing in gliomas is associated with 5′CpG island methylation and unfavourable prognosis. J Cell Mol Med. 13:4257–4267. 2009. View Article : Google Scholar : PubMed/NCBI
32	Briest F, Berndt A, Clement J, Junker K, Eggeling Fv, Grimm S and Friedrich K: Tumor-stroma interactions in tumorigenesis: Lessons from stem cell biology. Front Biosci (Elite Ed). 4:1871–1887. 2012. View Article : Google Scholar : PubMed/NCBI